Apritant 150mg Injection

Apritant 150mg Injection is a prescription based medication which is used to treat nausea and vomiting associated with cancer chemotherapy. It works by blocking the neurokinin -1 (NK1) receptor in the brain, thereby preventing the signals that trigger vomiting. Medication active ingredient is Fosaprepitant Dimeglumine, a prodrug that quickly turns into aprepitant in the body, helping prevent nausea and vomiting. This injection should be administered under the supervision of a healthcare professional.

Treat nausea and vomiting in cancer patients

● Fatigue
● Diarrhea
● Indigestion
● Anemia
● Skin blistering, peeling
● Low white blood cell count
● Anemia
● Anaphylactic reactions
● Urinary tract infection
● Rash, urticaria
● Itching
● Abnormal physical weakness
● Infection
● Nerve damage

Apritant 150mg Injection is an oral administration, taken with or without food at the fixed time everyday. Do not stop taking this medication without consultation of a healthcare provider to ensure safety and effectiveness of the treatment. Doctor suggest to regular monitor the liver function test while taking this medication. In case you missed a dose then it is better to take it as soon as possible to increase the effectiveness of the medication.

In cancer patients, nausea and vomiting are common symptoms. It can lead to dehydration and poor nutrition. Apritant 150mg Injection helps to reduce these symptoms by blocking neurokinin receptor which lowers both the symptoms nausea and vomiting. The medication is only used to cancer patients by improving patient comfort and enhances overall treatment outcomes.

• Garnock-Jones, K. P. (2016). Fosaprepitant dimeglumine: a review in the prevention of nausea and vomiting associated with chemotherapy. Drugs, 76(14), 1365-1372.
• Colon-Gonzalez, F., & Kraft, W. K. (2010). Pharmacokinetic evaluation of fosaprepitant dimeglumine. Expert opinion on drug metabolism & toxicology, 6(10), 1277-1286.
• Van Belle, S. J., & Cocquyt, V. (2008). Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting. Expert Opinion on Pharmacotherapy, 9(18), 3261-3270.
• Candelario, N., & Lu, M. L. R. (2016). Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives. Cancer Management and Research, 77-82.
• Cao, Z., Zhang, L., Huang, M., Xia, S., Sun, Y., Yu, X., ... & Xu, F. (2025). Development and Validation of an HPLC Method for the Simultaneous Determination of Eight Related Substances in Fosaprepitant Dimeglumine API. Chromatographia, 88(3), 205-214.